Esperion Therapeutics (NASDAQ:ESPR) Price Target & New Coverage by Deutsche Bank

Analysts at Deutsche Bank has initiated coverage on shares of Esperion Therapeutics (NASDAQ:ESPR) in analysts note issued to clients and investors on Friday, 23 June. The firm set Buy rating on the $985.84M market cap company.

Despite the new coverage NASDAQ:ESPR is currently trading 0.00% lower at $42.31 as of 8:06 AM New York time. Esperion Therapeutics shares have [From2] 0% over the past 200 days, while the S&P 500 has gained 6.00% in the same time.

According to data compiled by Thomson Reuters, Esperion Therapeutics (NASDAQ:ESPR)’s stock is covered by 12 equity analysts across the Street, with 0 analysts giving it a Sell rating, 11 a Buy rating, while 2 consider it a Hold. The 12-month consensus target price for the stock is $32.67, which reflects an downside potential of 22.78% over the current price.

Institutional Ownership

Aisling Capital Llc had the largest stake with ownership of 1.64M shares as of q2 2015 for 4.67% of the fund’s portfolio. Bvf Inc Il is another bullish institutional investor who is having 493,872 shares of Esperion Therapeutics or 1.29% of their fund’s portfolio. In addition, Bb Biotech Ag have 0.64% of their fund’s portfolio invested in the company for 1.31M shares. The Connecticut-based fund Discovery Capital Management Llc Ct revealed it had acquired a stake worth about 0.31% of the institutional investor’s stock portfolio in Esperion Therapeutics. The New York-based fund Iguana Healthcare Management Llc is also positive about the stock, possessing 1.05M shares or 0.2% of their fund’s portfolio.

Esperion Therapeutics (NASDAQ:ESPR) Profile

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Esperion Therapeutics (NASDAQ:ESPR) closed at $42.31 yesterday. A total of 12 shares of the company’s stock traded hands. This is down from average of 613,075 shares. Esperion Therapeutics has a 52 week low of $9.40 and a 52 week high of $48.21. The company has a market cap of $985.84M and a P/E ratio of 0.

Get the latest Esperion Therapeutics (NASDAQ:ESPR) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Deutsche Bank Has Started Coverage on Esperion Therapeutics (NASDAQ:ESPR) with Buy and with $48.0 Target appeared first on Octafinance.